Tsumura's Sales Drop 10% For Year
Japanese company Tsumura has reported a decline in consolidated sales of 9.7% to 115.8 billion yen ($1.15 billion) for the financial year ended March 1994.
Operating profits declined by 14.4% to 6.6 billion yen compared to the previous year. However, the company posted ordinary profits of 1.4 billion yen, a huge increase of 234% compared to 1993. Even so, a net loss of 2.1 billion for the year was reported by the company.
Pharmaceutical sales decreased 11% to just over 83 billion yen, with operating profits for the division amounting to 8.6 billion yen, an increase of 4% over the previous year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze